Prophylactic treatment of breast implants with a solution of gentamicin, vancomycin and cefazolin antibiotics for women undergoing breast reconstructive surgery: protocol for a randomised, double-blind, placebo-controlled trial (The BREAST-AB trial).

Autor:	Hemmingsen MN; Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark mathilde.nejrup.hemmingsen@regionh.dk., Larsen A; Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Weltz TK; Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Ørholt M; Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Wiberg S; Department of Anaesthesiology, Zealand University Hospital Koge, Køge, Denmark., Bennedsen AK; Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Bille C; Department of Plastic Reconstructive Surgery, Odense University Hospital, Odense, Denmark., Carstensen LF; Department of Plastic Surgery, Southwest Jutland Hospital, Esbjerg, Denmark., Jensen LT; Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Bredgaard R; Department of Plastic Surgery and Burns Treatment, Herlev og Gentofte, Copenhagen University Hospital, Herlev, Denmark., Koudahl V; Department of Plastic Surgery, Lillebaelt Hospital, Vejle, Denmark., Schmidt VJ; Department of Plastic and Breast Surgery, Zealand University Hospital Roskilde, Roskilde, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Vester-Glowinski P; Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Hölmich LR; Department of Plastic Surgery and Burns Treatment, Herlev og Gentofte, Copenhagen University Hospital, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Sørensen SJ; Department of Biology, Section of Microbiology, University of Copenhagen, Copenhagen, Denmark., Bjarnsholt T; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Damsgaard T; Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Herly M; Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2022 Sep 17; Vol. 12 (9), pp. e058697. Date of Electronic Publication: 2022 Sep 17.
DOI:	10.1136/bmjopen-2021-058697
Abstrakt:	Introduction: Periprosthetic infection is one of the most severe complications following implant-based breast reconstruction affecting 5%-10% of the women. Currently, many surgeons apply antibiotics locally on the breast implant to reduce the risk of postoperative infection, but no randomised, placebo-controlled trials have tested the treatment's efficacy. Methods and Analysis: The BREAST-AB trial (BREAST-AntiBiotics) is an investigator-initiated, multicentre, randomised, placebo-controlled, double-blind trial of local treatment with gentamicin, vancomycin and cefazolin on breast implants in women undergoing implant-based breast reconstruction. The trial drug consists of 80 mg gentamicin, 1 g vancomycin and 1 g cefazolin dissolved in 500 mL of isotonic saline. The placebo solution consists of 500 mL isotonic saline. The trial drug is used to wash the dissected tissue pocket and the breast implant prior to insertion. The primary outcome is all-cause explantation of the breast implant within 180 days after the breast reconstruction surgery. This excludes cases where the implant is replaced with a new permanent implant, for example, for cosmetic reasons. Key long-term outcomes include capsular contracture and quality of life. The trial started on 26 January 2021 and is currently recruiting. Ethics and Dissemination: The trial was approved by the Regional Ethics Committee of the Capital Region (H-20056592) on 1 January 2021 and the Danish Medicines Agency (2020070016) on 2 August 2020. The main paper will include the primary and secondary outcomes and will be submitted to an international peer-reviewed journal. Trial Registration Number: NCT04731025. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu